Trial record 18 of 47 for:    "Malignant fibrous histiocytoma"

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Genentech
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT00667342
First received: April 24, 2008
Last updated: July 30, 2013
Last verified: July 2013
  Purpose

This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). Chemotherapy for localized disease comprises a 3-drug regimen (cisplatin, doxorubicin, and high-dose methotrexate). Chemotherapy for metastatic or unresectable disease comprises a cisplatin-based regimen that includes high-dose methotrexate, doxorubicin, ifosfamide, and etoposide.


Condition Intervention Phase
Osteosarcoma
Malignant Fibrous Histiocytoma (MFH) of Bone
Biological: Bevacizumab
Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma

Resource links provided by NLM:


Further study details as provided by St. Jude Children's Research Hospital:

Primary Outcome Measures:
  • Feasibility [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    To study the feasibility of combining bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), with cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) in patients with localized resectable osteosarcoma, and bevacizumab with cisplatin, doxorubicin, HDMTX, ifosfamide, and etoposide in patients with unresectable or metastatic osteosarcoma.

  • Event Free Survival compared to historical controls on the Intergroup Study 0133 [ Time Frame: 7 years ] [ Designated as safety issue: No ]
    To study the effect of adding bevacizumab to chemotherapy comprised of cisplatin, doxorubicin, and HDMTX on the event-free survival (EFS) in patients with localized resectable osteosarcoma compared to historical controls treated with cisplatin, doxorubicin, and HDMTX without bevacizumab on the Intergroup Study 0133.


Secondary Outcome Measures:
  • Histologic response in patients with localized resectable osteosarcoma compared to Intergroup Study 0133 patients [ Time Frame: 5 years plus 6 cycles of chemotherapy ] [ Designated as safety issue: No ]
    To study the effect of adding bevacizumab to preoperative chemotherapy comprised of cisplatin, doxorubicin, and HDMTX on the histologic response in patients with localized resectable osteosarcoma compared to historical controls treated with preoperative cisplatin, doxorubicin, and HDMTX without bevacizumab on the Intergroup Study 0133.

  • Event free survival of patients with osteosarcoma [ Time Frame: 6 years ] [ Designated as safety issue: No ]
    To estimate the EFS and overall survival of patients with osteosarcoma treated with chemotherapy and bevacizumab.

  • Overall survival of patients with osteosarcoma [ Time Frame: 6 years ] [ Designated as safety issue: No ]
    To estimate the EFS and overall survival of patients with osteosarcoma treated with chemotherapy and bevacizumab.

  • Event free survival in patients with localized resectable disease compared to OS99 protocol. [ Time Frame: 6 years ] [ Designated as safety issue: No ]
    To compare outcomes (EFS and survival) of patients with localized resectable disease treated on this protocol vs. those treated on the OS99 protocol.

  • Overall survival in patients with localized resectable disease compared to OS99 protocol. [ Time Frame: 6 years ] [ Designated as safety issue: No ]
    To compare outcomes (EFS and survival) of patients with localized resectable disease treated on this protocol vs. those treated on the OS99 protocol.


Estimated Enrollment: 95
Study Start Date: May 2008
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
See intervention description.
Biological: Bevacizumab
Monoclonal Antibody against VEGF
Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)

Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide.

Participants with resectable localized disease (Stratum A) only receive cisplatin, methotrexate and doxorubicin.


Detailed Description:

This is a comprehensive study that uses a novel agent that targets angiogenesis (bevacizumab) in combination with conventional chemotherapy for the treatment of osteosarcoma. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor (VEGF), has been shown to stop the growth of new blood vessels of tumors, both in the laboratory and in patients with other types of cancers. Bevacizumab has improved the effect of chemotherapy in adult patients with different types of cancer by increasing tumor response and increasing the chances of survival. This study has two main goals:

  • To find out if bevacizumab can be combined safely with chemotherapy for osteosarcoma
  • To find out if adding bevacizumab to chemotherapy will be beneficial in treating osteosarcoma.

The chemotherapy drugs used in this study are commonly used to treat osteosarcoma. Patients with non-metastatic and resectable tumors receive bevacizumab and chemotherapy comprised of cisplatin, doxorubicin and high-dose methotrexate. Patients with metastatic tumors or tumors that cannot be removed by surgery receive bevacizumab and chemotherapy comprised of cisplatin, doxorubicin and high-dose methotrexate, ifosfamide and etoposide. If the tumor can be removed by surgery, surgery will be performed after 10 weeks of chemotherapy and will be followed by additional chemotherapy. After completion of active therapy, patient's response to therapy will be followed for approximately 5 years.

  Eligibility

Ages Eligible for Study:   up to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must have newly diagnosed high-grade, biopsy proven, osteosarcoma or malignant fibrous histiocytoma (MFH) of bone with no history of prior chemotherapy or radiation;
  • Participant is able to perform tasks and daily activities as defined in the study guidelines
  • Patient meets established guidelines for adequate function of the kidney, liver, heart and bone marrow
  • Participants meets other requirements defined in the eligibility portion of the study

Exclusion Criteria:

  • recent major surgical procedure or injury
  • Known bleeding diathesis, platelet disorder or coagulopathy
  • Thrombosis
  • Cardiac disease or hypertension
  • Significant proteinuria
  • Central nervous system disease
  • Gastrointestinal perforation/abdominal fistula
  • Osteosarcoma or MFH of bone as second malignancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00667342

Locations
United States, California
Rady Children's Hospital and Health Center
San Diego, California, United States, 92123
United States, Maryland
Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21231
NCI/NIH - Pediatric Oncology Branch
Bethesda, Maryland, United States, 20892
United States, Tennessee
St Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
St. Jude Children's Research Hospital
Genentech
Investigators
Principal Investigator: Fariba Navid, MD St. Jude Children's Research Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT00667342     History of Changes
Other Study ID Numbers: OS2008, GENENTECH PHARM
Study First Received: April 24, 2008
Last Updated: July 30, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Histiocytoma
Osteosarcoma
Histiocytoma, Benign Fibrous
Histiocytoma, Malignant Fibrous
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Bone Tissue
Sarcoma
Antibodies, Monoclonal
Methotrexate
Isophosphamide mustard
Bevacizumab
Cisplatin
Doxorubicin
Etoposide
Ifosfamide
Endothelial Growth Factors
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Radiation-Sensitizing Agents
Antibiotics, Antineoplastic
Antineoplastic Agents, Phytogenic
Antineoplastic Agents, Alkylating
Alkylating Agents

ClinicalTrials.gov processed this record on April 15, 2014